GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Amoy Diagnostics Co Ltd (SZSE:300685) » Definitions » Retained Earnings

Amoy Diagnostics Co (SZSE:300685) Retained Earnings : ¥1,071 Mil (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Amoy Diagnostics Co Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Amoy Diagnostics Co's retained earnings for the quarter that ended in Mar. 2024 was ¥1,071 Mil.

Amoy Diagnostics Co's quarterly retained earnings increased from Sep. 2023 (¥946 Mil) to Dec. 2023 (¥1,007 Mil) and increased from Dec. 2023 (¥1,007 Mil) to Mar. 2024 (¥1,071 Mil).

Amoy Diagnostics Co's annual retained earnings increased from Dec. 2021 (¥637 Mil) to Dec. 2022 (¥828 Mil) and increased from Dec. 2022 (¥828 Mil) to Dec. 2023 (¥1,007 Mil).


Amoy Diagnostics Co Retained Earnings Historical Data

The historical data trend for Amoy Diagnostics Co's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amoy Diagnostics Co Retained Earnings Chart

Amoy Diagnostics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 347.30 475.40 637.20 827.67 1,007.16

Amoy Diagnostics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 884.73 899.25 946.22 1,007.16 1,071.05

Amoy Diagnostics Co Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Amoy Diagnostics Co  (SZSE:300685) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Amoy Diagnostics Co (SZSE:300685) Business Description

Traded in Other Exchanges
N/A
Address
39 Dingshan Road, Haicang District, Xiamen, CHN, 361027
Amoy Diagnostics Co Ltd is the pharmaceutical company based in China. The company primarily focuses on molecular diagnostics for oncology precision medicine. It provides diagnostic products and services for medicine development and clinical oncology practice. The company's products include gene mutation, nucleic acid extraction, and molecular diagnostic kits comprising EGFR, RAS, ALK, BRAF, PIK3CA, and ROS1 testing kits.
Executives
Ruan Li Directors, executives
Zheng Hui Bin Directors, executives
Chen Ying Directors, executives
Luo Jie Min Executives
Zhu Guan Shan Directors, executives
Yang Shou Qian Securities Affairs Representative
Zhou Wen Gang Executives
Zhou Xue Lin Independent director
Hu Xu Bo Director

Amoy Diagnostics Co (SZSE:300685) Headlines

No Headlines